CytoDyn Updates
Share
Leronlimab (PRO 140), a CCR5 antagonist, is a viral-entry inhibitor currently being tested to treat HIV, cancer, GvHD, and now, COVID-19.
01/13/2022
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
01/12/2022
CytoDyn to Hold Webcast and Live Q/A on January 13 CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
01/12/2022
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
01/06/2022
CytoDyn reveals results from part two of Phase 2 NASH clinical trial CytoDyn Inc CEO Nader Pourhassan talks to Proactive about results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The Vancouver, British Colu...
01/05/2022
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
12/22/2021
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
12/22/2021
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
12/15/2021
12/13/2021
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
12/13/2021
CytoDyn to Hold Webcast and Live Q/A on December 14 CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
12/13/2021
https://www.youtube.com/watch?v=tSnmdAy0yig&t=4s
CytoDyn updates on Brazil and US COVID-19 trial progress, files expanded use for HIV MDR patients CytoDyn Inc. CEO Nader Pourhassan tells Proactive its contract research organization in Brazil has met with the Brazilian Health Regulatory Agency and receiv...
12/09/2021
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
Vancouver, WA